On September 10, 2021 Exscientia, which provides an AI-driven platform for drug design, discovery, and development,reported that it filed on Friday with the SEC to raise up to $100 million (Press release, Exscientia, SEP 10, 2021, View Source [SID1234587596]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Exscientia states that it is an artificial intelligence-driven pharmatech company that aims to discover, design, and develop the best possible drugs in the fastest and most effective manner. The company has built a complete end-to-end solution of AI and experimental technologies for target identification, drug candidate design, translational models, and patient selection. The company states that it has originated the first three AI-designed precision drug candidates to enter human clinical trials. Its most advanced internally developed candidate, EXS21546, began a Phase 1 trial in December 2020. The other two candidates, which are being developed by its collaboration partner Sumitomo Dainippon Pharma, are also currently in Phase 1 trials. Exscientia has designed four additional candidates currently undergoing advanced profiling for submission of INDs; the company has more than 25 active projects in total.

The Oxford, United Kingdom-based company was founded in 2012 and booked $14 million in revenue for the 12 months ended June 30, 2021. It plans to list on the Nasdaq under the symbol EXAI. Exscientia filed confidentially on June 21, 2021. Goldman Sachs, Morgan Stanley, BofA Securities, and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.